TrialSignal
Clinical trial intelligence report
A Multicenter, Open-label, Single Arm Phase IV Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05353192
Status
UNKNOWN
Phase
PHASE4
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Executive brief
Investment-Ready Snapshot
To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05353192
Indication
Achondroplasia
Modality
small molecule
Target
Recombinant human growth hormone
Intervention
Recombinant human growth hormone
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.